IntoCell, Inc. Logo

IntoCell, Inc.

Develops and licenses proprietary ADC platform technologies for cancer & immune therapies.

287840 | KO

Overview

Corporate Details

ISIN(s):
KR7287840003
LEI:
Country:
South Korea
Address:
대전광역시 대덕구 신일동로 101, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IntoCell, Inc. is a biotechnology company specializing in the research and development of novel biopharmaceuticals. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) platform technologies, including its OHPAS™ linker and Payload Modification Technology. IntoCell leverages these platforms to develop targeted therapies for cancer and immunological disorders. The company's business model is centered on the commercialization and transfer of its innovative ADC technologies to global partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (ITC6146RO의 한국 MFDS 제1상 임상시험계획 승인신청)
Korean 8.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 758.7 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-07-09 00:00
Regulatory News Service
투자판단관련주요경영사항 (ADC 플랫폼 기술에 대한 실시권 계약 해지)
Korean 6.6 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.8 KB
2025-06-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.6 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 73.6 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 185.8 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.6 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all IntoCell, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IntoCell, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IntoCell, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.